Wisp Review: Honest Look at Pricing, Plans, and Pros/Cons

Wisp is a sexual and reproductive health telehealth platform founded in 2018, headquartered in San Francisco. It was built specifically to address the gap in convenient, fast, non-judgmental access to treatment for conditions that primarily affect women: UTIs, vaginal infections, STIs, birth control, and sexual health. It has since expanded to include hormonal health, menopause care, and limited men's health categories.

The platform's operational model prioritizes speed. UTI treatment - one of its most commonly used services - is designed to move from symptom description to prescription in under an hour. The intake for well-understood conditions like UTIs and yeast infections is brief by design: if your symptoms clearly indicate the condition, the clinical decision is straightforward and the intake can be minimal without compromising safety.

Wisp holds an 8.5/10 rating across 16,200 reviews. The most consistently praised aspect is exactly what the platform promises: speed and ease for conditions that are frustrating to navigate through traditional care. The most common criticisms involve the cost of individual treatment courses for patients who experience recurrent conditions, and provider response time variability for less common conditions.

The platform is deliberately less complete than Hers or Ro across all women's health categories - it is not trying to be an all-in-one platform. It is trying to be the fastest, most accessible option for the specific conditions it specializes in.

Urinary tract infections affect approximately 50-60% of women at some point in their lives, and recurrent UTIs - three or more per year - affect approximately 25% of women who have had one. Despite how common and well-understood UTIs are, the traditional treatment pathway is unnecessarily slow: make a doctor's appointment, wait for availability, confirm the infection, get a prescription, go to the pharmacy. Wisp compresses this into a 30-60 minute process.

The Wisp UTI intake asks about symptom onset, symptom type (burning during urination, frequency, urgency, lower abdominal pain), whether you have fever or back pain (which can indicate kidney involvement), and relevant medical history. Uncomplicated UTIs - the most common type - have a clear clinical presentation and a well-established treatment protocol. A licensed provider reviews the intake and, if appropriate, sends a prescription for an appropriate antibiotic (typically nitrofurantoin or trimethoprim-sulfamethoxazole) to a pharmacy of your choice or ships it directly.

Wisp can also prescribe prophylactic antibiotics for women with recurrent UTIs - a clinical approach supported by ACOG guidelines for women with three or more documented UTIs per year. This means Wisp can serve as ongoing management infrastructure for recurrent UTI sufferers, not just a one-time treatment.

Patients with symptoms suggesting a complicated UTI - fever above 101°F, severe back pain, nausea, or vomiting - are directed to in-person care. This is correct clinical practice; complicated UTIs involving the kidneys require more complete evaluation than a telehealth intake can provide.

Bacterial vaginosis and yeast infections together account for approximately 90% of vaginal infection cases in women. BV responds to metronidazole or clindamycin; yeast infections to fluconazole or topical azoles. Both have well-established treatment protocols that are appropriate for telehealth management without physical examination.

The clinical challenge is distinguishing between BV and yeast infection based on symptoms alone, as they can present similarly. Wisp's intake asks about discharge characteristics (color, consistency, odor), which are the key distinguishing factors. For cases where symptoms are ambiguous, Wisp recommends testing rather than empiric treatment - a clinically appropriate approach that prevents the misdiagnosis that occurs when patients self-treat with OTC yeast infection products for what is actually BV.

STI testing at Wisp uses at-home test kits that patients complete themselves and mail back to a lab. Testing panels cover chlamydia, gonorrhea, syphilis, HIV, herpes, and hepatitis. Results are delivered through the patient portal and a licensed provider reviews positive results and prescribes treatment when appropriate. This creates a complete loop from testing to treatment without requiring an in-person clinic visit - valuable for patients in areas with limited STI clinic access.

Wisp prescribes oral contraceptive pills, patches, and vaginal rings. The ACA requires most insurance plans to cover all FDA-approved contraceptive methods at no cost-sharing - meaning many patients can access prescription birth control at zero out-of-pocket cost.

Hormonal health at Wisp covers hormone testing (at-home saliva or blood tests), consultation for hormonal imbalance symptoms (irregular periods, PCOS symptoms, perimenopause), and prescription treatment where appropriate. This is less complete than a gynecologist's full hormonal assessment but provides faster access to basic hormonal management for common presentations.

Menopause care at Wisp includes prescription hormone therapy for hot flashes, night sweats, and vaginal atrophy. The intake covers symptom severity, medical history, and contraindications for hormone therapy.

Wisp operates primarily on a per-condition pricing model rather than a flat monthly subscription, which is a meaningful structural difference from platforms like Hers. A UTI treatment course costs approximately $20-30 for the consultation and prescription. Yeast infection treatment is similar. Birth control is $15-25 per month depending on the contraceptive type.

This per-condition pricing makes Wisp cost-efficient for episodic conditions (UTI, yeast infection, BV) but potentially more expensive than a flat-rate subscription platform for women with multiple ongoing conditions. A woman managing birth control plus recurrent UTIs plus hormone therapy might find Hers' consolidated subscription approach more economical.

STI testing kits are priced individually at $75-150 depending on the panel. This is competitive with traditional clinic STI testing copays, particularly for patients with high-deductible plans.

Wisp accepts HSA and FSA cards for eligible medical expenses. It does not accept insurance for most services.

Wisp is best for women who primarily need fast, convenient access to treatment for acute reproductive and sexual health conditions. If you get UTIs frequently and want to be able to get a prescription the same day symptoms start rather than making a doctor's appointment, Wisp is built exactly for that.

Women who want STI testing without a clinic visit will find Wisp's at-home testing panels convenient and competitively priced.

Women managing ongoing birth control through telehealth who also want coverage for acute reproductive health conditions (UTI, yeast infection) in one platform will find Wisp efficiently serves both needs.

Hers covers more categories (weight loss, hair loss, mental health) but is less specialized in the reproductive and sexual health conditions Wisp treats. For acute UTI or vaginal infection treatment, Wisp's faster intake and more focused clinical content is the better experience.

Nurx competes most directly with Wisp - it started as a contraception platform and has expanded into STI testing and other women's health conditions. The two platforms are closely matched for birth control and STI testing; Wisp has a stronger clinical offering for vaginal infections specifically.

Wisp can send prescriptions to a local pharmacy of your choice (for immediate pickup if time is critical) or ship medications directly to your home. For acute conditions like UTIs where starting antibiotics quickly matters, the local pharmacy routing option is valuable.

STI test kits ship with pre-paid return envelopes. Results are typically available within 5-7 business days of the lab receiving the sample.

For complex gynecological conditions (PCOS management requiring multiple medication adjustments, endometriosis, pelvic inflammatory disease), Wisp's telehealth model is insufficient. These conditions require in-person examination, imaging, and the clinical continuity of an established OB-GYN relationship.

For women who want weight loss, hair loss, or mental health treatment in addition to reproductive health, Wisp does not cover those categories. Hers provides more complete multi-category coverage.

Recurrent infections that do not respond to standard first-line antibiotics require culture-guided treatment and in-person evaluation. Wisp is appropriate for uncomplicated, first-presentation UTIs and common vaginal infections - not for treatment-resistant cases.

Wisp does what it promises better than any competitor: fast, convenient, non-judgmental access to treatment for UTIs, yeast infections, BV, and sexual health conditions. The speed advantage is real - from symptom onset to prescription in under an hour for uncomplicated presentations. The specialization advantage is real - the clinical content and patient experience are tuned specifically for these conditions.

For women who need reproductive and sexual health coverage specifically, Wisp is the strongest specialized option. For women who want complete multi-category coverage, Hers is more efficient. Both can be used simultaneously for their respective strengths.

Rating: 8.5/10. Recommended for reproductive and sexual health treatment specifically.